BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 352 filers reported holding BIO-TECHNE CORP in Q1 2019. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $247,730,000 | -6.2% | 1,000 | 0.0% | 0.08% | -6.1% |
| Q2 2020 | $264,070,000 | +209.5% | 1,000 | +122.2% | 0.08% | +148.5% |
| Q1 2020 | $85,329,000 | -13.6% | 450 | 0.0% | 0.03% | +13.8% |
| Q4 2019 | $98,780,000 | +12.2% | 450 | 0.0% | 0.03% | 0.0% |
| Q3 2019 | $88,052,000 | -6.1% | 450 | 0.0% | 0.03% | +7.4% |
| Q2 2019 | $93,820,000 | +215.0% | 450 | +200.0% | 0.03% | +200.0% |
| Q1 2019 | $29,783,000 | -31.4% | 150 | -50.0% | 0.01% | -35.7% |
| Q4 2018 | $43,416,000 | -14.9% | 300 | +20.0% | 0.01% | 0.0% |
| Q3 2018 | $51,028,000 | +15.0% | 250 | -16.7% | 0.01% | +7.7% |
| Q2 2018 | $44,385,000 | -2.0% | 300 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $45,312,000 | +16.6% | 300 | 0.0% | 0.01% | +18.2% |
| Q4 2017 | $38,865,000 | +7.2% | 300 | 0.0% | 0.01% | +22.2% |
| Q3 2017 | $36,267,000 | +2.9% | 300 | 0.0% | 0.01% | +28.6% |
| Q2 2017 | $35,250,000 | -23.4% | 300 | -33.8% | 0.01% | -22.2% |
| Q1 2017 | $46,047,000 | +11.1% | 453 | +12.4% | 0.01% | +12.5% |
| Q4 2016 | $41,440,000 | -65.7% | 403 | -63.5% | 0.01% | -61.9% |
| Q3 2016 | $120,779,000 | -77.5% | 1,103 | -76.8% | 0.02% | -77.4% |
| Q2 2016 | $535,996,000 | +14.5% | 4,753 | -4.0% | 0.09% | +6.9% |
| Q1 2016 | $468,158,000 | +1.0% | 4,953 | -3.8% | 0.09% | +8.8% |
| Q4 2015 | $463,500,000 | -9.7% | 5,150 | -7.2% | 0.08% | +19.4% |
| Q3 2015 | $513,153,000 | -3.5% | 5,550 | +2.8% | 0.07% | +13.6% |
| Q2 2015 | $531,738,000 | -1.8% | 5,400 | 0.0% | 0.06% | -1.7% |
| Q1 2015 | $541,566,000 | – | 5,400 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |